MYL DMA
As of date:10/19/2020
MYL stock price:15.42
MYL 50 DMA:15.60
MYL 200 DMA:16.95
MYL MACD (200-50):1.35

Also see:
MYL Market Cap History
MYL Shares Outstanding History
MYL YTD Return
MYL RSI
MYL MACD
MYL Technical Analysis

Notable Two Hundred Day Moving Average Cross - EVLO
23 minutes ago


Voyager Therapeutics Breaks Below 200-Day Moving Average - Notable for VYGR
1 hour, 4 minutes ago


Bullish Two Hundred Day Moving Average Cross - PFLT
1 hour, 5 minutes ago


LNDC Makes Notable Cross Below Critical Moving Average
1 hour, 17 minutes ago


Newtek Business Services (NEWT) Shares Cross Below 200 DMA
1 hour, 18 minutes ago


AMGN Makes Notable Cross Below Critical Moving Average
1 hour, 23 minutes ago


ICU Medical (ICUI) Shares Cross Below 200 DMA
1 hour, 23 minutes ago


BOX Crosses Below Key Moving Average Level
1 hour, 31 minutes ago


Physicians Realty Trust (DOC) Shares Cross Below 200 DMA
1 hour, 33 minutes ago


Notable Two Hundred Day Moving Average Cross - EMD
1 hour, 37 minutes ago


Alexandria Real Estate Equities (ARE) Shares Cross Below 200 DMA
1 hour, 37 minutes ago


Notable Two Hundred Day Moving Average Cross - BWXT
1 hour, 38 minutes ago


FLR Crosses Above Key Moving Average Level
1 hour, 38 minutes ago


IIM Makes Notable Cross Below Critical Moving Average
1 hour, 38 minutes ago


Genpact Breaks Below 200-Day Moving Average - Notable for G
1 hour, 38 minutes ago


More Technical Analysis News

MYL DMAMYL MACD
Mylan is engaged in the global development, licensing, manufacture, marketing and distribution of generic, branded generic, brand-name and over-the-counter (OTC) pharmaceutical products for resale by others and active pharmaceutical ingredients (API) through three reportable segments on a geographic basis, North America, Europe and Rest of World. Co.'s API business is conducted through its subsidiary, Mylan Laboratories Limited, which is included within its Rest of World segment. Among Co.'s branded prescription products are EpiPen® Auto-Injector, Perforomist® Inhalation Solution and Dymista®. Co.'s OTC portfolio includes Cold-EEZE®, MidNite® and Vivarin®, as well as other products.

When researching a stock like Mylan NV, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from MYL Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for MYL stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the MYL 200 day moving average ("MYL 200 DMA"), while one of the most popular "shorter look-backs" is the MYL 50 day moving average ("MYL 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Mylan NV.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Quotes delayed 20 minutes
Get Free SEC filing alerts for MYL:
MYL SEC Filing Email Alerts ServiceExternal link
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Mylan NV (MYL) is categorized under the Healthcare sector; to help you further research DMA, below are some other companies in the same sector:

PFE DMA
PKI DMA
PRGO DMA
REGN DMA
RMD DMA
SYK DMA
TFX DMA
TMO DMA
UHS DMA
VAR DMA
More Healthcare companies »

 

MYL DMA | www.StockDMA.com | Copyright © 2019 - 2020, All Rights Reserved

Nothing in StockDMA.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.